4893 items matching your search terms.

Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials

Nagrial, A. M. Chin, V. T. Sjoquist, K. M. Pajic, M. Horvath, L. G. Biankin, A. V. Yip, D.
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 2015     DOI:10.1016/j.critrevonc.2015.07.007

Volumetric and dosimetric changes to salivary glands during radiotherapy for head and neck cancer

Najim, M. Perera, L. Bendall, L. Sykes, J. R. Gebski, V. Cross, S. Veness, M.
ACTA ONCOLOGICA, 2015     DOI:10.3109/0284186x.2015.1068951

What is normal bladder neck anatomy?

Naranjo-Ortiz, C. Shek, K. L. Martin, A. J. Dietz, H. P.
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2015     DOI:10.1007/s00192-015-2916-1

Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease

Nestel, P. Clifton, P. Colquhoun, D. Noakes, M. Mori, T. A. Sullivan, D. Thomas, B.
HEART, LUNG & CIRCULATION, 2015     DOI:10.1016/j.hlc.2015.03.020

The relative benefits and costs of solid phase bead technology to detect preformed donor specific antihuman leukocyte antigen antibodies in determining suitability for kidney transplantation

Nguyen, H. T. Lim, W. H. Craig, J. C. Chapman, J. R. Lord, S. J. Howard, K. Wong, G.
TRANSPLANTATION, 2015     DOI:10.1097/tp.0000000000000697

Evaluation of the Family Integrated Care model of neonatal intensive care: a cluster randomized controlled trial in Canada and Australia

O'Brien, K. Bracht, M. Robson, K. Ye, X. Y. Mirea, L. Cruz, M. Ng, E. Monterrosa, L. Soraisham, A. Alvaro, R. Narvey, M. Da Silva, O. Lui, K. Tarnow-Mordi, W. Lee, S. K.
BMC PEDIATRICS, 2015     DOI:10.1186/s12887-015-0527-0

Financial costs for families of children with type 1 diabetes in lower-income countries

Ogle, G. D. Kim, H. Middlehurst, A. C. Silink, M. Jenkins, A. J.
DIABETIC MEDICINE, 2015     DOI:10.1111/dme.12997

Brain Cancer Biobanking Australia

Olson, S. BCBA Steering Committee,

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

Ong, K. L. Januszewski, A. S. O’Connell, R. Buizen, L. Jenkins, A. J. Xu, A. Sullivan, D. R. Barter, P. J. Scott, R. S. Taskinen, M. R. Rye, K. A. Keech, A. C.
DIABETOLOGIA, 2015     DOI:10.1007/s00125-015-3652-2

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Ong, K. L. Januszewski, A. S. O'Connell, R. Jenkins, A. J. Xu, A. Sullivan, D. R. Barter, P. J. Hung, W. T. Scott, R. S. Taskinen, M. R. Keech, A. C. Rye, K. A.
DIABETOLOGIA, 2015     DOI:10.1007/s00125-014-3458-7

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Oza, Amit M. Cook, Adrian D. Pfisterer, Jacobus Embleton, Andrew Ledermann, Jonathan A. Pujade-Lauraine, Eric Kristensen, Gunnar Carey, Mark S. Beale, Philip Cervantes, Andrés Park-Simon, Tjoung-Won Rustin, Gordon Joly, Florence Mirza, Mansoor R. Plante, Marie Quinn, Michael Poveda, Andrés Jayson, Gordon C. Stark, Dan Swart, Ann Marie Farrelly, Laura Kaplan, Richard Parmar, Mahesh K. B. Perren, Timothy J.
LANCET ONCOLOGY, 2015     DOI:http://dx.doi.org/10.1016/S1470-2045(15)00086-8

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): a randomized placebo-controlled trial

Park, S.B. Vucic, S. Cheah, B.C. Lin, C.S.Y. Kirby, A. Mann, K.P. Zoing, M.C. Winhhammar, J. Kiernan, M.C.
EBIOMEDICINE, 2015     DOI:10.1016/j.ebiom.2015.11.022

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk

Patel, A. Cass, A. Peiris, D. Usherwood, T. Brown, A. Jan, S. Neal, B. Hillis, G. S. Rafter, N. Tonkin, A. Webster, R. Billot, L. Bompoint, S. Burch, C. Burke, H. Hayman, N. Molanus, B. Reid, C. M. Shiel, L. Togni, S. Rodgers, A.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015     DOI:10.1177/2047487314530382

INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG), first results.

Pavlakis, M. Sjoquist, K.M. Tsobanis, E. Martin, A. Kang, Y.K. Bang, Y.J. O'Callaghan, C.J. Tebbutt, N.C. Rha, S.Y. Lee, J. Cho, J.Y. Lipton, L.R. Burnell, M.J. Alcindor, T. Strickland, A. Wong, M. Kim, J.W. Simes, J. Zalcberg, J.R. Goldstein, D.

INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)—final overall and subgroup results

Pavlakis, N. Sjoquist, K.M. Tsobanis, E. Martin, A.J. Kang, Y. K. Bang, Y.J. O'Callaghan, C.J. Tebbutt, N.C. Rha, S.Y. Cho, J.Y. Lipton, L.R. Burnell, M.J. Alcindor, T. Strickland, A. Kim, J.W. Yip, S. SImes, J. Zalcberg, J. Goldstein, D.